Literature DB >> 7519211

Identification of two novel regions of human IL-6 responsible for receptor binding and signal transduction.

M Ehlers1, J Grötzinger, F D deHon, J Müllberg, J P Brakenhoff, J Liu, A Wollmer, S Rose-John.   

Abstract

The pleiotropic cytokine IL-6 has been predicted to be a protein with four antiparallel alpha-helices. Human IL-6 acts on human and murine cells, whereas murine IL-6 is only active on murine cells. The construction of a set of chimeric human/murine IL-6 proteins has recently allowed us to define a new region (residues Lys41-Glu95) within the IL-6 molecule as being important for receptor binding and biologic activity. We subdivided and analyzed this region, which primarily corresponds to the loop between the first and second alpha-helix of IL-6 with respect to its role in the interaction with the ligand binding subunit of the IL-6 receptor complex and with the IL-6 signal-transducing protein gp130. By construction and analysis of human/murine chimeric IL-6 molecules with only 7 to 10 amino acid residues different from human IL-6 we show that two distinct parts of this region are responsible for receptor binding and signal transduction. On the basis of the recently published structure of granulocyte-CSF, we present a three-dimensional model for the tertiary structure of IL-6, which, together with the IL-6 receptor interaction data, allows for the rational design of human IL-6 receptor antagonists.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7519211

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  21 in total

1.  Engineering human interleukin-6 to obtain variants with strongly enhanced bioactivity.

Authors:  C Toniatti; A Cabibbo; E Sporena; A L Salvati; M Cerretani; S Serafini; A Lahm; R Cortese; G Ciliberto
Journal:  EMBO J       Date:  1996-06-03       Impact factor: 11.598

2.  Forced dimerization of gp130 leads to constitutive STAT3 activation, cytokine-independent growth, and blockade of differentiation of embryonic stem cells.

Authors:  Christiane Stuhlmann-Laeisz; Sigrid Lang; Athena Chalaris; Paliga Krzysztof; Sudarman Enge; Jutta Eichler; Ursula Klingmüller; Michael Samuel; Matthias Ernst; Stefan Rose-John; Jürgen Scheller
Journal:  Mol Biol Cell       Date:  2006-04-19       Impact factor: 4.138

Review 3.  Activating mechanism of CNTF and related cytokines.

Authors:  M Inoue; C Nakayama; H Noguchi
Journal:  Mol Neurobiol       Date:  1996-06       Impact factor: 5.590

4.  Detection of direct binding of human herpesvirus 8-encoded interleukin-6 (vIL-6) to both gp130 and IL-6 receptor (IL-6R) and identification of amino acid residues of vIL-6 important for IL-6R-dependent and -independent signaling.

Authors:  H Li; H Wang; J Nicholas
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

Review 5.  Interleukin-6: structure-function relationships.

Authors:  R J Simpson; A Hammacher; D K Smith; J M Matthews; L D Ward
Journal:  Protein Sci       Date:  1997-05       Impact factor: 6.725

6.  Human ciliary neurotrophic factor: a structure-function analysis.

Authors:  A Krüttgen; J Grötzinger; G Kurapkat; J Weis; R Simon; M Thier; M Schröder; P Heinrich; A Wollmer; M Comeau
Journal:  Biochem J       Date:  1995-07-01       Impact factor: 3.857

7.  In vitro and in vivo antitumor effects of the recombinant immunotoxin IL6(T23)-PE38KDEL in multiple myeloma.

Authors:  DE-Jun Guo; Jia-Shan Han; Yan-Song Li; Zeng-Shan Liu; Shi-Ying Lu; Hong-Lin Ren
Journal:  Oncol Lett       Date:  2012-05-25       Impact factor: 2.967

8.  Functional characterization of W147A: a high-affinity interleukin-11 antagonist.

Authors:  Nicholas Underhill-Day; Lisa A McGovern; Natalia Karpovich; Helen J Mardon; Victoria A Barton; John K Heath
Journal:  Endocrinology       Date:  2003-08       Impact factor: 4.736

9.  Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop.

Authors:  H C van Zaanen; R P Koopmans; L A Aarden; H J Rensink; J M Stouthard; S O Warnaar; H M Lokhorst; M H van Oers
Journal:  J Clin Invest       Date:  1996-09-15       Impact factor: 14.808

10.  Unraveling viral interleukin-6 binding to gp130 and activation of STAT-signaling pathways independently of the interleukin-6 receptor.

Authors:  Nina Adam; Björn Rabe; Jan Suthaus; Joachim Grötzinger; Stefan Rose-John; Jürgen Scheller
Journal:  J Virol       Date:  2009-03-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.